<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="7" ids="16670">Peptide</z:chebi>-mediated immunotherapy has been studied in a number of experimental models of <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> and has also been tested in human patients to a certain extent </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="5" ids="53310">Copolymer</z:chebi> 1 is a synthetic amino acid <z:chebi fb="5" ids="53310">copolymer</z:chebi> that has been demonstrated to suppress experimental autoimmune <z:mp ids='MP_0006082'>encephalomyelitis</z:mp> (a model for multiple <z:mp ids='MP_0000612'>sclerosis</z:mp>) when administered parenterally </plain></SENT>
<SENT sid="2" pm="."><plain>Some study results indicate that mucosal tolerance induced by appropriate recombinant <z:chebi fb="7" ids="16670">peptide</z:chebi> fragments of human AChR is effective in suppressing experimental autoimmune <z:hpo ids='HP_0003473'>myasthenia</z:hpo> gravis and might be considered as a therapeutic modality for patients with MG </plain></SENT>
<SENT sid="3" pm="."><plain>A <z:chebi fb="7" ids="16670">peptide</z:chebi> of the heat-shock protein 60 molecule, designated <z:chebi fb="7" ids="16670">peptide</z:chebi> p277, was shown to be a target of T cells in autoimmune <z:mp ids='MP_0002055'>diabetes</z:mp> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e> mice, and intraperitoneal injections of glutamic acid decarboxylase (GAD) <z:chebi fb="7" ids="16670">peptide</z:chebi> 524-543 delayed the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:mp ids='MP_0002055'>diabetes</z:mp> and significantly reduced its incidence </plain></SENT>
<SENT sid="4" pm="."><plain>Experimental evidence has revealed that CDR-based <z:chebi fb="7" ids="16670">peptides</z:chebi> may be potential candidates for the therapy of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The use of synthetic <z:chebi fb="7" ids="16670">peptides</z:chebi> that focus on neutralization of pathogenic anti-beta 2GPI antibodies represents a possible new therapeutic approach to <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Studies in both <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo>-relapsing experimental autoimmune uveoretinitis have indicated that oral administration of S-Ag, S-Ag-derived <z:chebi fb="7" ids="16670">peptides</z:chebi>, inter-photoreceptor <z:chebi fb="0" ids="26537">retinoid</z:chebi> binding protein or HLA-derived <z:chebi fb="7" ids="16670">peptides</z:chebi> before immunization can protect animals from the disease </plain></SENT>
</text></document>